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U nlike most mature cells, smooth muscle cells (SMCs) are remarkably plastic and can dedifferentiate in response to environmental cues, 1,2 adding a layer of complexity to the regulation of gene expression. Although several transcription factors have been identified, a global mechanism that coordinately regulates SMC phenotype has yet to be uncovered. How SMC genes become silenced and then reactivated is unknown and is an area of intense investigation. Recent demonstration that the ten-eleven-translocation (TET) family of proteins is involved in DNA demethylation [3] [4] [5] prompted us to evaluate the role of the TET proteins in the modulation of SMC phenotype.
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The TET proteins (TET1-TET3) are a recently discovered family of DNA demethylases. TET proteins oxidize 5-methylcytosine (5-mC) to generate 5-hydroxymethylcytosine (5-hmC), frequently called the sixth DNA base, in mammalian cells. 4, 5 Through the base excision repair pathway, 5-hmC is then converted to unmethylated cytosine, leading to DNA demethylation and gene activation. [6] [7] [8] Therefore, the 5-hmC modification and the TET enzymes have emerged as key activators of gene expression. Studies of TET proteins and 5-hmC function in embryonic stem cells (ESCs) demonstrate that they play a major role in maintaining cellular pluripotency through the regulation of lineage-specific genes. 4, [9] [10] [11] In contrast to this role in ESC pluripotency, the TET proteins (and their 5-hmC products) have an opposing role in adult stem cells and somatic tissues. TET2 mutations have been described in several types of hematopoietic disorders in which the loss of TET2 has been shown to promote hematopoietic stem cell self-renewal.
12 TET2 and 5-hmC levels are increased during neurogenesis, 13 and more recently, loss of TET2 and 5-hmC was demonstrated to be a key epigenetic event associated with Background-Smooth muscle cells (SMCs) are remarkably plastic. Their reversible differentiation is required for growth and wound healing but also contributes to pathologies such as atherosclerosis and restenosis. Although key regulators of the SMC phenotype, including myocardin (MYOCD) and KLF4, have been identified, a unifying epigenetic mechanism that confers reversible SMC differentiation has not been reported. Methods and Results-Using human SMCs, human arterial tissue, and mouse models, we report that SMC plasticity is governed by the DNA-modifying enzyme ten-eleven translocation-2 (TET2). TET2 and its product, 5-hydroxymethylcytosine (5-hmC), are enriched in contractile SMCs but reduced in dedifferentiated SMCs. TET2 knockdown inhibits expression of key procontractile genes, including MYOCD and SRF, with concomitant transcriptional upregulation of KLF4. TET2 knockdown prevents rapamycin-induced SMC differentiation, whereas TET2 overexpression is sufficient to induce a contractile phenotype. TET2 overexpression also induces SMC gene expression in fibroblasts. Chromatin immunoprecipitation demonstrates that TET2 coordinately regulates phenotypic modulation through opposing effects on chromatin accessibility at the promoters of procontractile versus dedifferentiation-associated genes. Notably, we find that TET2 binds and 5-hmC is enriched in CArG-rich regions of active SMC contractile promoters (MYOCD, SRF, and MYH11). Loss of TET2 and 5-hmC positively correlates with the degree of injury in murine models of vascular injury and human atherosclerotic disease. Importantly, localized TET2 knockdown exacerbates injury response, and local TET2 overexpression restores the 5-hmC epigenetic landscape and contractile gene expression and greatly attenuates intimal hyperplasia in vivo. Conclusions-We identify TET2 as a novel and necessary master epigenetic regulator of SMC differentiation. aggressive melanoma. 14 Collectively, these studies suggest a cell-or tissue-specific effect of the TET proteins and the 5-hmC mark on gene activation.
Here, we present data using both in vitro and in vivo knockdown and overexpression approaches to functionally characterize the role of TET2 and its 5-hmC product in regulating the SMC phenotype. We find that TET2 expression is necessary for SMC differentiation and that TET2 binds to the SRF and MYOCD promoters under differentiation conditions. Additionally, we show that TET2 regulates the cellular program by directly modulating chromatin accessibility of target genes. Furthermore, we report that TET2-activated gene promoters are enriched with the 5-hmC mark, resulting in strong gene activation. Overall, we demonstrate a novel epigenetic pathway by which contractile and synthetic genes are regulated simultaneously in SMCs. In addition to demonstrating a critical role for TET2 in adult somatic cells in health and disease, our study suggests that targeting the TET2-5-hmC pathway may be a therapeutic strategy for the treatment of diseases associated with aberrant SMC differentiation.
Methods
Please refer to the online-only Data Supplement for an extended description of the materials and methods. Primer sequences for qualitative polymerase chain reaction (qPCR) analysis of gene expression are provided in Tables I and II in 
Human Atherosclerotic Tissues
Research protocols were approved by the Institutional Review Boards of the West Haven VA Hospital, Yale University, and the New England Organ Bank. Informed consent was obtained, and human coronary arteries were obtained as previously described. 15, 16 The presence of atherosclerosis was documented at the time of cardiac procurement by an experienced cardiac surgeon. Pliable, translucent coronary arteries were deemed normal and designated healthy controls. Opaque coronary arteries were classified as atherosclerotic to various degrees (mild, moderate, and severe). The macroscopic diagnosis was confirmed by histology.
Femoral Artery Wire Injury
All experiments were approved by the Institutional Animal Care and Use Committees of Yale University and performed in adherence to the National Institutes of Health's Guide for the Care and Use of Laboratory Animals. Femoral arteries were injured as previously described. 17, 18 For localized virus delivery, viruses (1×10 7 plaque-forming units) were delivered to the artery at the time of injury by painting the virus mixture (15 µL concentrated viral supernatant and 35 µL Pluronic-127 gel) circumferentially around the injured femoral artery. The injured and uninjured femoral arteries were collected for cryosectioning 3 weeks after surgery.
Cell Culture
Human coronary artery SMCs (hCASMCs) were purchased from Cascade Biologics (Portland, OR) and cultured as previously described. [19] [20] [21] [22] MRC5 cells were purchased from ATCC and cultured in 10% FBS. Human umbilical vein endothelial cells (HUVEC) were cultured in EBM-2 basal medium and associated supplements (Lonza Biologicals). Cells from passages 4 through 7 were used for all experiments.
Chromatin Immunoprecipitation-qPCR
Chromatin immunoprecipitation was performed as previously described with slight modifications. 23 Briefly, 5×10 6 Table III in the online-only Data Supplement. All samples were performed in at least triplicate from at least 2 independent experiments, and data were normalized to percent input.
Methylated-DNA Capture
Enrichment of methylated DNA was performed with the methylated-DNA capture (MethylCap) kit (Diagenode). 24 Genomic DNA was diluted to 0.1 μg/μL and then sheared to 200 to 500 bp. Methylated DNA was captured by incubation with a His6-GST-MBD protein (the methyl-binding domain of the human MeCP2 protein fused with a glutathione-S-transferase and containing an N-terminal His6-tag) coupled to magnetic beads. The beads were washed and DNA eluted. The methyl-binding domain-bound (methylated) and input fractions were analyzed by qPCR to confirm enrichment of the methylated genes. Primer sequences can be found in Table III in the online-only Data Supplement.
Hydroxymethylated DNA Immunoprecipitation
Immunoprecipitation of 5-hmC was performed with the hydroxymethylated DNA immunoprecipitation kit (Diagenode) per the manufacturer's instructions. Samples were sonicated as for methylated-DNA capture, and 1 μg fragmented genomic DNA was immunoprecipitated with a 5-hmC antibody. The DNA-antibody mixture was incubated with magnetic beads and washed, and the DNA was isolated. End-point analysis was performed with locus-specific hydroxymethylated DNA immunoprecipitation-qPCR. Primer sequences are listed in Table III in the online-only Data Supplement.
Glucosylation-Coupled Methylation-Sensitivity qPCR
Sequence-specific detection of 5-hmC and 5-mC as a percentage of total C was performed with the Quest 5-hmC Detection Kit (Zymo Research) based on published methods. 11 Genomic DNA (1 μg) was treated with T4 Phage β-glucosyltransferase, a highly specific 5-hmC glucosyltransferase, that adds a glucose moiety to 5-hmC (generating glucosyl-5-hmC). Glucosylated genomic DNA was then digested with MspI, which recognizes and cleaves mC, 5-mC, and 5-hmC but not glucosyl-5-hmC. Locus-specific detection of 5-hmC was determined by qPCR using primers designed to flank at least 1 MspI site. Primer sequences used are listed in Table IV in the online-only Data Supplement.
Dot Blot
Cellular genomic DNA was isolated with the Qiagen kit; genomic DNA from tissue sections was isolated with the Pinpoint Slide DNA Isolation System (Zymo Research). DNA was blotted onto a nitrocellulose membrane and incubated with anti-5-hmC (1:10000, Active Motif) overnight at 4°C. After incubation with horseradish peroxideconjugated IgG secondary antibody, the signal was visualized with enhanced chemiluminescence reagents. Methylene blue staining of the membranes was used to assess equal DNA loading.
Statistical Analysis
Data are expressed as mean±SD. Comparisons between 2 groups were calculated with the Mann-Whitney test. The Kruskal-Wallis test, followed by the Dunn multiple-comparison test, was performed for data between >2 groups. P values were 2 tailed, and values of P<0.05 were considered to indicate statistical significance. Analyses were performed with Prism 4.0 software (GraphPad). Intraclass correlation coefficients were calculated with an online tool (http://department. obg.cuhk.edu.hk/researchsupport/IntraClass_correlation.asp).
Results

TET2 and 5-hmC Are Upregulated During SMC Differentiation
The role of the TET family of enzymes in an adult somatic cell such as SMCs is yet to be determined. We evaluated the expression of TET proteins in hCASMC cultures and found TET2 to be the most highly expressed isoform in these cells ( Figure 1A ). Remarkably, TET2 transcript and protein levels were significantly higher in hCASMCs compared with human ESCs. To explore a possible role for the TET family members in modulating the SMC phenotype, we induced SMC differentiation by treatment with the mTORC1 inhibitor rapamycin 21, 22 or dedifferentiation with platelet-derived growth factor-BB (PDGF-BB). 25 Both TET2 transcript and protein levels were elevated with differentiation but repressed with PDGF-BB treatment ( Figure 1B . Given its abundant expression and modulation during SMC differentiation, we focused our further studies on TET2. We determined that Tet2 is abundantly expressed in multiple SMC-rich murine tissues ( Figure II in the online-only Data Supplement). In the vasculature, Tet2 was highly expressed in SMCs isolated from the medial layer of normal mouse aorta but dramatically decreased with culture in 10% serum, in parallel with Myh11 expression ( Figure 1C ). These levels were partially rescued with rapamycin ( Figure 1C ). Because the enzymatic function of the TET proteins is to convert 5-mC to 5-hmC, 4 ,5,9 we measured 5-hmC levels in SMCs. Genomic dot blot analysis revealed a global increase in 5-hmC levels in differentiated SMCs and reduced 5-hmC levels in dedifferentiated cultures ( Figure 1D ). These results demonstrate that both TET2 and its 5-hmC product correlate with the SMC differentiated phenotype.
TET2 and 5-hmC Levels Are High in Mature SMCs and Are Reduced After Vascular Injury and Disease
To understand the physiological role of TET2 and 5-hmC in vivo, we examined TET2 and 5-hmC expression in murine and human models of vascular injury and disease. Intimal hyperplasia was induced with the mouse femoral artery wire injury model. 18 In the uninjured vessels, Tet2-expressing cells made up >95% of the total number of medial cells (n=4). Tet2-expressing cells were reduced in the injured medial layer, and only 16% of cells in the neointima were Tet2 positive at 3 weeks after injury (n=5; Figure 2A , quantified in Figure 2B ). RNA analysis further confirmed that vessel injury reduced the levels of Tet2 and contractile genes in the media and neointima ( Figure 2C ). The 5-hmC staining ( Figure 2A , quantified in Figure 2D ) and genomic levels ( Figure 2E ) closely paralleled Tet2 expression patterns. These results support our in vitro findings that high Tet2 and 5-hmC levels are associated with the mature, differentiated SMC phenotype, whereas significant loss of Tet2 and 5-hmC is characteristic of dedifferentiated SMC.
We next sought to assess TET2 and 5-hmC levels in human vascular disease. SMC dedifferentiation is a major contributor to atherosclerosis. 26, 27 We analyzed human coronary artery biopsies from 16 individuals with normal arteries or demonstrating mild, moderate, or severe atherosclerosis. MYH11 staining was used to identify differentiated SMCs within the individual patient samples. MYH11 intensity inversely correlated with the severity of disease, and TET2 expression correlated closely with the MYH11 staining ( Figure 3A , quantified in Figure 3B ). Consistently, global 5-hmC levels were also significantly reduced in atherosclerotic samples ( Figure 3C ). Taken together, these results implicate TET2 and its product, 5-hmC, as novel biomarkers for diseases associated with SMC dedifferentiation.
Disruption of TET2 Results in Impaired SMC Differentiation
To assess a causal role for TET2 in SMC phenotypic modulation, we generated shRNA constructs targeting the human TET2 gene (shTET2; Figure IIIA in the online-only Data Supplement). TET2 knockdown was highly efficient and specific ( Figure IIIB in the online-only Data Supplement). Significant reductions in SMC differentiation gene expression and 5-hmC levels were observed with TET2 knockdown in hCASMCs ( Figure 4A-4C) . We found that TET2 is an obligate effector of rapamycin-induced differentiation because TET2 knockdown prevented rapamycin-induced contractile gene expression ( Figure 4D ) and morphology ( Figure IIIC in the online-only Data Supplement). Additionally, we observed enhanced proliferation in shTET2 cultures as determined by propidium iodide staining and flow cytometry ( Figure 4E ), and mRNA levels for cyclins and cyclin-dependent kinase inhibitors supported these observations (data not shown). TET2 knockdown also significantly increased the expression of markers associated with the synthetic SMC phenotype such as KLF4, [28] [29] [30] [31] KLF5, 32 osteopontin, 33 and embryonic type nonmuscle myosin heavy chain-B (MYH10) 34 
Ectopic Expression of TET2 Directs SMC Differentiation
Because TET2 knockdown and overexpression had such profound effects on the SMC phenotype, we investigated whether ectopic expression of TET2 is sufficient to convert fibroblasts into mature SMCs. The human fetal lung fibroblast line MRC5 expressed moderate levels of TET2 at baseline compared with hCASMCs. After 5 days of infection with lentivirus to overexpress TET2, TET2 levels were elevated almost 3-fold compared with control MRC5 cells. However, this was still less than the level of TET2 expression observed at baseline in hCASMCs ( Figure 4I ). Moderate levels of ACTA2 and low levels of MYH11 were observed in MRC5 cells at baseline as detected by Western blot and immunostaining ( Figure 4I and 4J, top). Introduction of TET2 into these fibroblasts was sufficient to upregulate numerous SMC markers such as ACTA2, MYH11, SRF, and MYOCD as detected by Western blot, . The fibroblast marker S100A4 was also reduced with TET2 overexpression in MRC5 and NIH3T3 cells ( Figure VA and VB in the online-only Data Supplement). These results demonstrate that activation of an SMC program in non-SMCs can be achieved with TET2. Interestingly, TET2 overexpression in human umbilical vein endothelial cells upregulated only some SMCspecific genes such as MYH11 and ACTA2, whereas SRF and TAGLN remained unchanged. MYOCD mRNA was not detectable (data not shown), and levels of the endothelium-specific genes PECAM1 and CDH5 remained relatively unchanged ( Figure VC and VD in the online-only Data Supplement).
Localized Delivery of TET2 Enhances SMC Differentiation and Can Improve Vascular Repair
To assess the role of TET2 in SMC differentiation in vivo, we performed localized delivery of control, TET2-knockdown, or TET2-overexpressing viruses to the site of femoral arterial wire injury. At 3 weeks after injury, injured femoral arteries treated with a control virus showed moderate intimal hyperplasia, whereas local delivery of the TET2 knockdown virus markedly increased the neointimal area ( Figure 5A ). In stark contrast, arteries transduced with the TET2-overexpression virus showed significant suppression of neointimal hyperplasia ( Figure 5A and 5B and Figure Figure 5D , top). Expression of these genes was further reduced in the injured arteries transduced with the TET2-knockdown virus ( Figure 5D , middle). In the injured femoral arteries transduced with TET2-overexpressing viruses, enhanced expression of Myh11 ( Figure 5D ) and Acta2 ( Figure VIIA in the online-only Data Supplement) was noted relative to the control injured samples. In addition, Tet2 and 5-hmC nuclear staining was also more evident throughout these injured samples ( Figure 5D , bottom).
To further assess the effect of TET2 knockdown or overexpression on the injured vessels, we examined whether TET2 modulation affected endothelial recovery or changes in mononuclear cell infiltration. Complete endothelial recovery was observed in all treatment groups as detected by CD31 staining, and no differences in leukocyte (CD45) or macrophage (CD68) staining were noted (Figure VIIA in the online-only Data Supplement). We observed significant upregulation of Col1a1, Col4a1, Col8a1, and Col8a2 in the control injured and TET2-knockdown injured samples compared with uninjured samples, whereas significant decreases in Col4a and Col8a2 expression were observed in the injured TET2-overexpression samples compared with injured control samples ( Figure VIIB and VIID in the online-only Data Supplement). No significant differences in the cyclins or cyclin-dependent kinase inhibitors were observed between the groups at 3 weeks ( Figure VIIC and VIIE in the online-only Data Supplement). Collectively, these data highlight that loss of TET2 diminishes the 5-hmC epigenetic landscape and plays a causative role in intimal hyperplasia after injury, whereas reintroduction of TET2 potently antagonizes intimal hyperplasia.
TET2 Binds to Key SMC Promoters and Modifies Histones at These Promoters
The effects of TET2 on SMC phenotypic modulation suggested the possibility of a direct interaction between TET2 and master SMC genes that control SMC differentiation. To test this notion, we used chromatin immunoprecipitation coupled with qPCR. We used an anti-TET2 antibody to immunoprecipitate protein/DNA complexes from hCASMCs treated with vehicle, rapamycin, or PDGF-BB for 24 hours and Figure 1E. October 29, 2013 qPCR amplified CArG-containing regions of the human SRF, MYOCD, and MYH11 promoters. Consistent with increased TET2 expression in SMC differentiation, TET2 binding to these promoters greatly increased during SMC differentiation induced by rapamycin ( Figure 6A ).
Because TET2 is known to promote DNA demethylation, 3, 5 we further sought to understand TET2-regulated epigenetic changes in SMC genes and evaluated the chromatin state of various SMC loci. We performed chromatin immunoprecipitation-qPCR, immunoprecipitating with antibodies recognizing the H3K4me3 (active) or H3K27me3 (inactive) marks and amplifying critical CArG-containing promoter regions of contractile SMC genes. Chromatin immunoprecipitation analysis of control, untreated hCASMCs cultured in 10% FBS revealed a euchromatic conformation at the MYOCD, SRF, and MYH11 gene promoters (H3K4me3/H3K27me3 ratios of 2.5, 9, and 1.9, respectively; Figure MYH11gene loci in hCASMCs, so that H3K4me3/H3K27me3 ratios were decreased by 3-to 8-fold ( Figure 6B-6D ). In contrast, H3K4me3/H3K27me3 ratios were increased by >4-fold at the KLF4 loci after TET2 knockdown ( Figure 6E ). These results are consistent with the differentiation defects observed with TET2 knockdown in hCASMCs ( Figure 4 ) and indicate that TET2 differentially regulates the chromatin accessibility of contractile and dedifferentiation genes in an opposing manner.
Promoters of Genes Upregulated by TET2 Are Enriched for 5-hmC
5-hmC levels have been associated with gene activation; therefore, we next used several methods to quantify locusspecific 5-hmC expression at key contractile SMC promoters. We determined the effect of TET2 knockdown on locus-specific 5-hmC levels by glucosylation-coupled methylation-sensitivity qPCR 11 and hydroxymethylated DNA immunoprecipitation-qPCR. The MYOCD, SRF, and MYH11 promoters become hypermethylated in shTET2 cells compared with shCTRL cells (Figure 6F , 6H, and 6J), accompanied by a significant and consistent decrease in 5-hmC levels relative to shCTRL cells at these loci ( Figure 6G , 6I, and 6K). TET2 overexpression increased 5-hmC levels at these loci ( Figure IXA online-only Data Supplement). Taken together, these data indicate that TET2 regulates SMC phenotype through the regulation of 5-hmC, which, in turn, affects chromatin modification of key SMC genes. These data support a primary role for 5-hmC as a distinct epigenetic mark in SMC differentiation.
Discussion
In the present work, we identify TET2 as a novel epigenetic master regulator of SMC plasticity that acts upstream of both MYOCD/SRF and KLF4. Using both in vitro and in vivo approaches, we demonstrate that TET2 is necessary and sufficient for SMC differentiation and that ectopic expression of TET2 is sufficient to direct SMC differentiation in fibroblasts. Endogenous TET2 is regulated by stimuli that modulate differentiation, including PDGF-BB and mTORC1 inhibition in vitro and after vascular injury in vivo. We report a striking correlation between diminished TET2 and 5-hmC expression and severity of atherosclerosis in human coronary arteries.
Most notably, we demonstrate a causal role for TET2 in SMC phenotypic modulation in response to arterial injury because TET2 loss of function exacerbates intimal hyperplasia after injury, whereas TET2 overexpression greatly attenuates intimal hyperplasia.
The unique phenotypic plasticity of SMC is known to be transcriptionally regulated, with MYOCD/SRF [35] [36] [37] [38] [39] and KLF4 28, 30 having been identified as key drivers of this plasticity, promoting the contractile and dedifferentiated phenotypes, respectively. Although these proteins interact with other factors that modulate chromatin, 37,40,41 a unifying upstream regulator that promotes global changes in chromatin at both contractile and synthetic gene promoters has never before been identified. It is therefore particularly notable that we now report that TET2 functions as an upstream regulator of these genes. The epigenetic changes regulated by TET2 have broad effects on chromatin, resulting in induction of MYOCD, SRF, and contractile genes, with concomitant repression of KLF4 and other dedifferentiation-associated genes. TET2 broadly affects SMC phenotype in vitro, including gene expression, morphology, and proliferation, and this translates to corresponding effects on intimal hyperplasia in vivo, including changes in expression of Myocd, Myh11, and collagen gene expression. The TET2 knockout mouse is viable and fertile but susceptible to spontaneous myeloid leukemias. 42 Although it was dispensable during development, our data suggest that TET2 plays an important role during the response to vascular injury in the adult.
Mechanistically, we demonstrate that TET2 binding directly to the SRF, MYOCD, and MYH11 promoters is strongly enriched in differentiated SMCs and coordinately regulates phenotypic modulation through opposing effects on chromatin accessibility at contractile compared with synthetic gene promoters. We propose that the potent effects of TET2 are attributable to its multiple modes of action, including binding directly to SM-specific promoters, regulating expression of the key transcription factors MYOCD and SRF, and inhibiting the repressor KLF4. TET2 alters DNA methylation, 5hmC modification, and histone methylation at these promoters.
Most studies of TET proteins to date have focused on embryonic and hematopoietic stem cells. Our study is the first to address the function of the TET proteins and the 5-hmC epigenetic mark in myocytes. We provide the first evidence that the 5-hmC modification correlates with the mature SMC phenotype and marks active contractile SMC gene promoters. Recent studies indicate that 5-hmC may represent more than just an intermediate base in the TET-mediated demethylation pathways; rather, it may have a larger role in regulating selfrenewal and lineage commitment. 14, 42, 43 Genome-wide analyses in mouse ESCs have shown that altering DNA methylation via TET1 and 5-hmC also affects histone methylation, 44, 45 adding to the complexity by which the TET proteins may regulate gene expression. We find that modulation of TET2, and subsequently 5-hmC, results in robust changes in histone methylation. A summary of our epigenetic data and schematic model is shown in Figure 7 . The finding that 5-hmC modulates not only local DNA cytosine methylation but also histone methylation suggests that 5-hmC, generated by TET2, does not simply represent an intermediate in the 5-mC demethylation process but functions as an epigenetic mark that modulates the SMC phenotype through recruitment of as-yet unidentified factors to promote chromatin remodeling.
High-throughput screening in mouse ESCs revealed that 5-hmC-expressing regions are enriched for both the H3K4 and H3K27 trimethylation marks, 45 where TET1 has been shown to maintain ESC identity by promoting the transcription of pluripotency-related factors while simultaneously participating in the silencing of developmental genes. 44 We now identify a similar pattern of chromatin regulation in SMCs and demonstrate that TET2 and 5-hmC have a similar dual function in adult SMCs: TET2 promotes a euchromatic conformation at promoters of contractile-associated genes while concomitantly inducing a repressive chromatin state at promoters of dedifferentiation-associated genes. Furthermore, using the recently established glucosylation-coupled methylation-sensitivity qPCR technique and a modified hydroxymethylated DNA immunoprecipitation protocol with the newly developed 5-hmC antibody, we were able to specifically and efficiently label 5-hmC at SMC gene promoter regions. This locus-specific analysis found that 5-hmC is abundant in active SMC promoters and low in promoters that are not transcribing, consistent with the notion that promoter hydroxymethylation leads to demethylation and gene activation. 11, 44, 45 The mechanisms by which TET2 mediates opposing effects on differentiation and dedifferentiation genes require further investigation. By activating the promoters of key transcription factors, including MYOCD, SRF, and MYH11, while repressing the KLF4 promoter, TET2 serves as an epigenetic master regulator of SMC differentiation. The concomitant activation of the promoters of MYOCD/SRF target genes (MYH11 and ACTA2) may account for the potent prodifferentiation effects of TET2 ( Figure 6 ). We noted TET2 binding to promoter regions containing CArG elements in contractile promoters, including a putative CArG element in the human MYOCD promoter, but important questions such as whether TET2 also interacts with non-CArG-rich regions of these promoters and what directs TET2 repression of synthetic gene promoters require further investigation. Our data reveal that TET2 and 5-hmC levels are modulated by environmental signals in SMCs. TET2 mRNA, protein, and 5-hmC levels are repressed by PDGF-BB, the major stimulus of SMC dedifferentiation in vivo and in vitro. Additionally, our data identify TET2 as a critical effector of the mTORC1 pathway in modulating SMC phenotype. We report that TET2 expression is regulated in part by the mTORC1 pathway because rapamycin induces TET2 expression at both the mRNA and protein levels and TET2 knockdown prevents rapamycin-induced differentiation. We have previously shown that mTORC1 inhibition promotes SMC differentiation at the level of transcription, 21, 22 and rapamycin-eluting stents are highly effective against restenosis. 46 Our data that local TET2 delivery to an injured artery prevents intimal hyperplasia suggest that manipulation of TET2 and 5-hmC expression may Figure 7 . Proposed model of smooth muscle cell (SMC) phenotypic modulation control by ten-eleven-translocation-2 (TET2). Vascular injury releases a milieu of growth factors, including platelet-derived growth factor BB (PDGF-BB), that can activate the mTORC1 pathway and promote SMC dedifferentiation to the synthetic phenotype. Rapamycin, an inhibitor of mTORC1, induces SMC differentiation. We now provide the first study to show that the mTORC1 pathway regulates SMC differentiation through regulation of TET2. In SMCs, the balance between contractile and synthetic gene expression is governed by TET2, which results in changes in chromatin conformation and 5-hydroxymethylcytosine (5-hmC) modifications at key promoters. An open chromatin conformation (as assessed by high levels of H3K4me3 and low expression of H3K27me3) and high levels of 5-hmC are seen at procontractile gene promoters in differentiated SMCs, whereas TET2 promotes a closed chromatin formation at the KLF4 promoter. October 29, 2013 have important therapeutic implications for other diseases involving aberrant SMC plasticity, including cancer, aneurysm, transplant vasculopathy, and hypertension.
Although TET2 mRNA has been reported to be expressed by many tissues, we noted that TET2 is very highly expressed in SMCs relative to other TET family members. Our data suggest that despite persistent expression levels of TET1 and TET3, these enzymes do not compensate for TET2 knockdown or downregulation by PDGF-BB in SMCs. We also observed robust TET2 expression in SMC-rich tissues and in cultured SMCs relative to other cell types (fibroblasts and endothelial cells). TET2 overexpression was sufficient to induce a program of SMC-specific gene expression in human and mouse fibroblasts, similar to what has been reported for MYOCD overexpression in myoblasts, 35 ESCs, 47 and 10T1/2 and 3T3 cells. 38 We found very low-level TET2 expression in human umbilical vein endothelial cells compared with SMCs. We achieved a modest overexpression of TET2 in human umbilical vein endothelial cells that was still below that seen in SMC at baseline, and this induced only a subset of SMC genes. It is therefore possible that there is a threshold effect such that high levels of TET2 regulate SMC-specific genes. It is also feasible that as-yet unidentified cell typespecific factors or other permissive chromatin modifications cooperate with TET2 in SMCs and in fibroblasts.
Conclusions
This is the first report of TET protein function in myocytes and the first demonstration of a TET protein regulated by the mTORC1 signaling pathway. Our data reveal that modulating TET2 and, in turn, 5-hmC levels results in broad epigenetic changes in methylation and histones indicative of altered chromatin formations at both differentiation-and dedifferentiation-specific SMC genes. Our findings support TET2 as a master epigenetic regulator of SMC phenotypic modulation. Altering key components of the TET2-5-hmC pathway may be a therapeutic target for treating diseases involving aberrant SMC plasticity that is involved in many cardiovascular associated disorders.
